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Abstract 
Background: The present paper reports on studies that evaluated artesunate + sulfadoxine‑pyrimethamine 
(AS + SP) which is the first‑line drug and artemether‑lumefantrine (AL) which is a second‑line drug against uncompli‑
cated falciparum malaria in Sudan. This evaluation was performed in twenty studies covering six sentinel sites during 
five successive annual malaria transmission seasons from 2010 to 2015.
Methods: The standard World Health Organization protocol was used for a follow‑up period of 28 days. The fre‑
quency distribution of molecular markers for antifolate resistance in dihydrofolate reductase (dhfr) and dihydropter‑
oate synthase (dhps) genes was studied in pre‑treatment samples in four sites in 2011.
Results: In the nine studies of AL conducted at five sites (n = 595), high PCR‑corrected cure rates were found, rang‑
ing from 96.8 to 100 %. Among the eleven studies of AS + SP (n = 1013), a decline in the PCR‑corrected cure rates 
was observed in Gedaref in Eastern Sudan: 91.0 % in the 2011–12 season and 86.5 % in the 2014–15 season. In the 
remaining sites, the AS + SP cure rates ranged between 95.6 and 100 %. The rate of clearance of microscopic game‑
tocytaemia after treatment was not significantly different with AL or AS + SP on days 7, 14, 21 and 28 of follow‑up. A 
total of 371 pre‑treatment samples were analysed for molecular markers of SP resistance. The temporal changes and 
geographical differences in the frequency distribution of SP‑resistance genotypes showed evidence of regional dif‑
ferentiation and selection of resistant strains.
Conclusion: The findings of this study call for a need to review the Sudan malaria treatment policy. Epidemiological 
factors could play a major role in the emergence of drug‑resistant malaria in eastern Sudan.
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Background
Malaria in Sudan is mainly caused by Plasmodium fal-
ciparum (95  % of cases), followed by P. vivax (5  %). 
Among the population of 37.9 million, 87 % live in areas 
of high malaria transmission, and the remaining live 
in areas of low transmission [1]. By 2004, the preva-
lence of chloroquine-resistant falciparum malaria was 
excessively high, leading the National Malaria Control 
Programme (NMCP) to change its malaria treatment 
policy. Chloroquine was replaced by artesunate  +  sulf-
adoxine-pyrimethamine (AS + SP) as the first-line treat-
ment policy for uncomplicated falciparum malaria and 
artemether-lumefantrine (AL) was adopted as a second-
line treatment [2].
Around the time when AS  +  SP was adopted as the 
first-line treatment for falciparum malaria, a number of 
therapeutic efficacy studies evaluated SP in Sudan, either 
as a monotherapy or in combination with other anti-
malarials [3]. These studies reported variable rates of 
treatment failure with SP monotherapy, reaching 31.7 % 
in eastern Sudan in 2003 [4]. Therapeutic efficacy stud-
ies (TES) for anti-malarial drugs are the gold standard for 
guiding anti-malarial treatment policy. The World Health 
Organization (WHO) recommends that studies of first- 
and second-line anti-malarial medicines should be con-
ducted once every 2  years at sentinel sites within each 
country [5]. Molecular markers for SP resistance provide 
supporting evidence and can predict resistance to SP to a 
reasonable extent [6]. These markers could provide a very 
convenient and cost effective tool to monitor changes in 
the prevalence of drug-resistant parasites. An increasing 
prevalence of alleles of genes known to confer resistance 
to a drug can provide an early warning of developing 
resistance [7]. Equally, a decrease in resistant alleles can 
be an indication of returning sensitivity when a drug is 
withdrawn [8, 9]. Molecular marker surveys could also 
greatly extend the coverage of resistance monitoring in 
areas where in  vivo tests are not feasible, even though 
they do not replace in vivo tests. This paper reports the 
results of therapeutic efficacy studies on AL and AS + SP 
conducted in Sudan from 2010 to 2015. An analysis of 
molecular markers conferring resistance to SP resistance 
is provided for four sentinel sites studied in 2011.
Methods
Study sites
Figure  1 shows the six sentinel sites and the states cov-
ered. The transmission season was from July/August to 
November/December, with an earlier start in June in the 
southern areas (e.g., Damazin) and a later start in August 
in northern areas (e.g., Kassala). Longer transmission 
takes place in certain agricultural areas, while the urban 
cities may have another transmission during winter 
(December–February) due to broken water pipes [10]. 
The studies were conducted during the malaria transmis-
sion season in each site between 2010 and 2015.
Study population
Patients were included if they met the following cri-
teria: age 6  months or above, asexual parasitaemia of 
500–100,000/µl, no mixed malaria infection, axillary tem-
perature ≥37.5 °C or a history of fever within 24 h, ability 
to swallow medication, ability to report for follow-up, and 
informed consent. Patients were excluded if they had dan-
ger signs in children under 5 years of age, signs of severe 
malaria, concomitant febrile illness other than malaria, 
mixed infection or infection with another species, or were 
pregnant or lactating. Female minors from menarche 
to 18  years and unmarried women above 18  years were 
also excluded due to social and cultural norms related to 
requesting a pregnancy test from this population.
Sample size
Estimation of the sample size in each site was based on an 
assumption of treatment failure of 5 %, with a 95 % con-
fidence level and precision of 5  %. Therefore, the target 
sample size in each study was 88 cases. This was based 
on a calculated minimum sample size of 73 cases, with 
approximately 20  % more to allow for loss to follow-up 
and withdrawals during follow-up. In two AL studies in 
the towns of Gedaref and Sennar, the malaria transmis-
sion rates in 2013–14 and 2014–15 were too low and the 
intended sample size could only be achieved in two con-
secutive seasons. It was decided to analyse the cases from 
each season separately, although this meant a smaller 
sample size than originally intended in four studies.
Ethical considerations
The studies presented were part of the Sudan NMCP sur-
veillance of therapeutic efficacy of anti-malarial drugs. 
Permission to conduct these studies was obtained from 
the Federal Ministry of Health of Sudan and the WHO 
ethical review committee and community leaders. Prior 
to enrolment, individual informed consent was read to 
all study patients. Consent was requested from guardians 
of children aged less than 17 years. In addition, an assent 
form was signed by children aged 12–17 years old. If the 
patient or parent/guardian was illiterate, the study infor-
mation was read to each patient/guardian in the presence 
of a witness known to the patient or a community leader.
Treatment and follow‑up
The studies were one-arm prospective studies, conducted 
according to the standard WHO protocol for monitoring 
therapeutic efficacy of anti-malarials against uncompli-
cated falciparum malaria for 28  days [5]. Treatment in 
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the AL studies and in and the AS + SP studies was given 
according to the dose regimens and therapeutic ranges 
recommended for each drug by WHO guidelines [11]. 
AL and AS  +  SP tablets used in the studies were pro-
vided by the WHO.
Rescue medication
Patients who developed danger signs and/or severe 
malaria were given parenteral artesunate, according to 
the national treatment policy. Treatment failures after 
AL were treated with quinine and treatment failures after 
AS + SP were re-treated with AL.
Laboratory methods
Thick and thin blood films for malaria microscopy 
were prepared, stained with Giemsa and examined, as 
described by the WHO [12]. All blood smears were 
checked by a second microscopist and discordant results 
with differences in species or in parasite density of were 
re-read by a third microscopist, and the average of the 
two most concordant readings was taken.
Genotyping at baseline and recurrent infections
Blood samples were collected on filter paper (Whatman® 
3MM, GE Healthcare UK Ltd. Buckinghamshire, Eng-
land) at enrolment and at any visit where parasites were 
observed on and after day 7. Filter papers were dried 
and each sample was stored in a separate plastic bag 
containing silica gel. All filter papers were subsequently 
transferred to Naval Medical Research Unit (NAMRU-
3) (through the WHO Eastern Mediterranean Regional 
Office) for analysis. DNA was extracted from blood spots 
Fig. 1 Map of Sudan showing six sentinel sites for therapeutic efficacy tests in Sudan 2010–2015. “X” indicates the location of three villages where 
isolates were collected in previous SP molecular marker studies in 2003. Pie charts indicate the proportion with quintuple/sextuple mutations. Black 
segments indicate the percentage of samples with quintuple or sextuple mutations in each site
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using the QIAamp® DNA Mini Kit (Qiagen, Hilden Ger-
many) as described by the manufacturer. Parasite DNA 
was extracted from blood spots on day 0 and on the day 
of reappearance of asexual parasitaemia. Blood samples 
were tested by nested PCR for msp1, msp2 (merozo-
ite surface proteins) and glurp (glutamate-rich protein) 
as described [13]. Samples of recurrent parasitaemia 
from day 7 onwards were tested by PCR to distinguish 
between re-infection and recrudescence according the 
WHO definitions [13]. If only two of the three loci could 
be amplified in paired samples and the PCR fragments in 
the paired samples were completely different in at least 
one locus, then the recurrent parasitaemia is considered 
a new infection. If the paired samples have at least one 
identical band and this was found at both loci amplified 
the recurrent sample was considered a recrudescence, 
even if some alleles were missing or new alleles were 
observed in the recurrent sample. If only one locus could 
be amplified and this marker indicates recrudescence, 
with shared bands, the sample was defined as recrudes-
cence. When it was not possible to distinguish recrudes-
cence from new infection, the sample was classified as 
indeterminate (unknown).
Genotyping for SP‑resistance genes
Mutations conferring resistance to SP were detected 
by analysing extracted DNA from all day 0 samples to 
determine the mutations in the dihydrofolate reductase 
(dhfr) and dihydropteroate synthase (dhps) genes in four 
AS + SP studies performed in 2011. Both dhfr and dhps 
genes were amplified using nested PCR as described 
elsewhere [14]. PCR products were subjected to DNA 
sequencing using BigDye terminator chemistry (Applied 
Biosystems, Foster City, CA, USA) on a 3130 × l Genetic 
Analyzer (Applied Biosystems, Foster City, CA). DNA 
sequences were assembled and mutations were verified 
by the inspection of both forward and reverse strands 
using BioEdit version 7.2.5. [15]. DNA sequencing analy-
sis of the dhfr fragment was carried out to detect muta-
tions at codons 16, 51, 59, 108 and 164, whereas the dhps 
fragment was evaluated at codons 436, 437, 540, 581 and 
613.
Statistical analysis
Data were analysed with a computer program developed 
by the WHO [5]. This software included the classification 
of treatment outcomes according to WHO definitions, 
with and without PCR, using per-protocol and Kaplan–
Meier survival analysis. Patients who were excluded or 
withdrew after enrolment were not included in the per 
protocol analysis of treatment outcomes. In the Kaplan–
Meier survival analysis, all such cases were included until 
the day of withdrawal from the study. Gametocyte carrier 
rates were compared between the two treatment groups 
using the Chi square test and survival analysis. Person 
gametocytaemia week (PGW) rates were calculated for 
each treatment group as the total number of weeks in 
which blood slides positive for gametocytes in all patients 
during a two-week follow-up, divided by the total num-
ber of follow-up weeks and expressed per 1000 person-
weeks [16]. The Chi square test was used to compare the 
prevalence rates of haplotypes among four different sites 
included in the 2011 survey and also to assess temporal 
changes in the prevalence of rates haplotypes in Gedaref 
between 2011 results and 2003 published data. Fisher’s 
exact test was used for observations less than five. Anal-
ysis of variance (ANOVA) was used to test for differ-
ences between baseline study population characteristics. 
Regression analysis was used to test association of treat-
ment failure with patient variables. Statistical analysis was 
performed using SPSS ® software version 22, SPSS Inc., 
Chicago, USA). For comparison of pairs of categorical 
variables Chi square test was performed using Epi-Info 7 
(CDC, Atlanta, GA and the WHO, Geneva, Switzerland).
Results
Efficacy studies on AL
The characteristics of the study population in nine AL 
studies are shown in Table 1. One-way ANOVA showed 
that there were differences between the sites in the mean 
age of the patients (F = 4.322, p < 0.001), mean tempera-
ture at baseline (F = 5.010), p = 0.002) and asexual para-
site density at baseline (F = 11.980), p < 0.001). Table 2 
shows the treatment outcomes based on per-protocol 
analysis and the cumulative incidence of treatment suc-
cess (Kaplan–Meier survival analysis) with or without 
PCR correction. The PCR-corrected cumulative inci-
dence of treatment success ranged from 96.8 to 100  %. 
Except for two cases (one classified as ETF on day 2 and, 
therefore, not tested for parasitaemia on day 3, and the 
other case classified as ACPR), all patients had complete 
clearance of microscopic asexual parasitaemia on day 3. 
The dosages of AL taken by the treatment failure cases 
were checked, and they were all found to be within the 
therapeutic range [11]. Cases of AL treatment failure 
showed no remarkable epidemiological pattern.
Efficacy studies on AS + SP
Eleven therapeutic efficacy tests were conducted to eval-
uate AS  +  SP efficacy. The characteristics in the study 
population in each site are shown in Table  1. ANOVA 
showed no significant difference in gender (F  =  1.692, 
p =  0.078), but there were significant differences in the 
mean age (F = 5.852, p < 0.001), the mean body tempera-
ture at baseline (F =  21.030, p < 0.001) and the asexual 
parasite density at enrolment (F = 15.936, p = 0.001).
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The lowest PCR-corrected cure rates in the AS +  SP 
studies were reported in two studies in Gedaref (Table 2). 
The first study, performed in 2011-12, reported a cure 
rate of 91.0  % (95  % CI 83.4–95.2). The second study, 
performed in the 2014-15 season, reported a cure rate 
of 86.5  % (95  % CI 77.5–92.1). In the other studies, the 
cure rates of AS +  SP ranged between 95.6 and 100  %. 
The dosages of AS + SP taken by treatment failure cases 
were checked and they were confirmed to be within the 
recommended therapeutic range [11].
When tested by binary logistic regression, the PCR-
corrected treatment failure had no significant asso-
ciation with the baseline characteristics of gender, body 
temperature and parasite density. However, there was 
significant association with age of the patient (Wald Chi 
square =  10.062, p =  0.002). The rate of treatment fail-
ure in Gedaref was significantly higher than all other 
studies (21/179  =  11.7  % versus 17/731  =  2.3  %), Chi 
square  =  31.794, OR 5.582 (95  % CI 2.879–10.825). In 
the two Gedaref studies, the rate of treatment failure in 
children under 5 was significantly higher than in adults 
(≥15 years), (8/28 = 28.6 % versus 2/51 = 3.9 %, Fisher’s 
exact test, p = 0.003).
Gametocytaemia after treatment
The baseline prevalence of gametocytaemia in the two 
treatment groups was not significantly different: 2.4  % 
in the ASSP group and 3.9  % in the AL group (Chi 
square  =  3.999, p  =  0.083, OR 1.663, 95  % CI 0.930–
2.973). Figure 2 is a Kaplan–Meier plot showing the time 
to clearance of gametocytes in gametocyte-positive indi-
viduals by microscopy at enrolment and during follow-
up. In the AL group, there was a reduction of 56.5 % in 
the proportion of patients with gametocytaemia by day 
7. The reduction from baseline by days 14, 21 and 28 
were 73.9, 82.6, and 87.0 %, respectively. The proportions 
of patients with gametocytaemia in the two treatment 
groups were not significantly different on days 7, 14, 21 
and 28. Of those who were gametocyte-negative at base-
line, there was no significant difference in the propor-
tion of patients who developed gametocytaemia during 
follow-up in the AL group (4/572, 0.9 %) compared to the 
ASSP group (16/958, 1.7 %), Fisher’s exact test, p = 0.242. 
There was no significant difference between the two 
treatment groups in the gametocyte carriage rates, meas-
ured as gametocytaemia per 1000 person-weeks, 17.7 
Table 1 Demographic and clinical characteristics of patient in therapeutic efficacy studies to evaluate artemether-lume-
fantrine or artesunate + sulfadoxine-pyrimethamine in Sudan (2010–2015)
SD standard deviation
Drug Site Study years N Males Age group Temperature D0Parasite count (/uL), D0
<5 years 5–14 years ≥15 years
N (%) N (%) N (%) N (%) Mean (SD) Geometric 
mean
Range
AS + SP Kosti 2010 92 57 (62) 14 (15) 59 (64) 19 (21) 38.1 (1) 26,202 (5470–90,940)
Sennar 2010 97 51 (53) 5 (5) 69 (71) 23 (24) 38.4 (0.9) 13,973 (1800–71,889)
Gedaref 2011–12 100 53 (53) 17 (17) 52 (52) 31 (31) 39 (1.1) 11,725 (1600–129,167)
Kassala 2011 75 44 (59) 24 (32) 17 (23) 34 (45) 38.1 (0.8) 5917 (1020–68,421)
Kosti 2011 98 55 (56) 17 (17) 63 (64) 18 (18) 38.1 (1.1) 14,249 (3380–88,098)
Sennar 2011 95 43 (44) 9 (10) 71 (75) 15 (16) 37.9 (1.2) 10,592 (1400–57,910)
Kosti 2012–13 95 45 (47) 20 (21) 58 (61) 17 (18) 37.1 (1.1) 18,541 (1120–97,143)
Damazin 2013–14 100 61 (61) 19 (19) 67 (67) 14 (14) 37.7 (1) 15,657 (1460–90,000)
Sennnar 2013–14 88 57 (65) 9 (10) 76 (86) 3 (3) 37.1 (0.9) 8252 (1140–35,500)
New Halfa 2013–14 80 40 (50) 14 (18) 25 (31) 41 (51) 38.6 (1.8) 12,798 (2123–116,666)
Gedaref 2014–15 93 47 (51) 15 (16) 58 (62) 20 (22) 37.6 (0.9) 11,165 (1053–52,319)
AL Damazin 2010 67 32 (48) 0 (0) 30 (45) 37 (55) 38.2 (0.6) 11,203 (1675–100,000)
Kassala 2010 85 57 (67) 11 (13) 40 (47) 34 (40) 37.8 (1) 11,245 (1500–97,142)
Kosti 2012–13 101 64 (63) 7 (7) 44 (44) 50 (50) 38.2 (0.9) 5339 (1000–45,756)
Damazin 2013 98 54 (55) 11 (11) 64 (65) 23 (24) 38.1 (0.9) 12,095 (3020–70,961)
Kassala 2013–14 84 53 (63) 12 (14) 32 (38) 40 (48) 38 (0.7) 16,226 (1100–90,000)
Sennar 2013–14 42 22 (52) 5 (12) 26 (62) 11 (26) 38.5 (1.2) 18,695 (3280–93,939)
Gedaref 2013–14 35 26 (74) 1 (3) 10 (29) 24 (69) 37.6 (0.9) 8524 (1060–75,000)
Sennar 2014 41 22 (54) 8 (20) 25 (61) 8 (20) 37.8 (1.1) 10,827 (1040‑78,110)
Gedaref 2014–15 42 29 (69) 7 (17) 23 (55) 12 (29) 37 (1.1) 4741 (1300–14,240)
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with AL and 20.2 with ASSP, RR 0.89, 95 % CI 0.62–1.28, 
p = 0.53.
Comparison of molecular markers of SP resistance 
among four sites in 2011
Molecular markers of SP resistance were studied in sam-
ples collected in 2011 from four sites: Kassala, Gedaref, 
Kosti and Sennar. Genetic mutations associated with SP 
resistance in dhfr and dhps were successfully analysed in 
365 and 366 samples, respectively, and mutation combi-
nations were identified in both genes in 361 samples.
Table  3 shows an analysis of the mutations detected 
in the dhfr gene in four sites. Gedaref had a signifi-
cantly higher frequency of the dhfr triple mutant 
N51I  +  C59R  +  S108  N than Kassala, Kosti and Sen-
nar. Table  4 shows an analysis of the haplotypes in the 
dhps gene. The frequency of the wild-type dhps haplo-
type differed by site, and it was significantly higher in 
Kosti than in Gedaref, Kassala and Sennar. The domi-
nant resistant dhps haplotype was the double mutant 
A437G  +  K540E. The dhps triple mutant haplotype 
A437G  +  K540E  +  A581G, which predominated in 69 
samples, was detected only in one sample in Kosti but in 
40.7  % of samples from Kassala, 15.6  % in Gedaref and 
20 % in Sennar.
Table  5 shows the distribution of mutations for the 
two-locus haplotypes of the combined dhfr and dhps 
genes. The most frequent mutation combinations were 
quadruple mutations (n  =  111) followed by double 
mutations (n  =  97) and quintuple mutations (n  =  87). 
The dominant haplotype was the quadruple mutation 
N51I + S108 N/A437G + K540E (n = 106). The propor-
tion of isolates with quintuple or sextuple haplotypes 
was highest in Kassala (38/79  =  48.1  %). This was not 
significantly higher than in Gedaref ([37/96  =  38.5  %], 
Chi square = 1.617, p = 0.2035), but it was significantly 
higher than in Kosti ([4/92 = 4.4 %], Fisher’s exact test, 
p < 0.001) and in Sennar [(18/98 = 18.4 %), Fisher’s exact 
test, p < 0.001]. The proportion of isolates with quintuple 
or sextuple mutations in each of the four sites studied is 
shown in the map indicating the geographical location of 
the sites (Fig.  1). Among the analysed isolates collected 
for four sites in 2011, there were nine treatment failures 
in whom the two-locus genotyping was successful. This 
number was too small for a meaningful analysis of the 
association between treatment failure and molecular 
markers.
Comparison of molecular markers from Gedaref in 2003 
and 20011
To assess the changes over time in the dhfr and dhps 
genotypes in Gedaref, comparisons were made with 
published reports by Al-Saai et  al., who studied iso-
lates collected in 2003 from Asar village, which located 
approximately 16 kilometres south of Gedaref town 
[17, 18], and with findings reported for isolates col-
lected in 2003 from the two villages of Daraweesh and 
Kajara located a few hundred meters apart at a distance 
of 15  km south of Gedaref town (locations indicated in 
the map, Fig. 1) [19]. For the sake of assessing temporal 
changes, we assume that all of these neighbouring locali-
ties represent the Gedaref site. The most notable change 
was observed in the triple mutant N51I/C59R/S108  N 
which was absent [17] or observed in very low frequency 
of 0.6 % [19] in 2003 samples but in 2011, it escalated to 
Fig. 2 Time to disappearance of microscopic gametocytaemia 
in gametocyte‑positive individuals at enrolment and following 
treatment. AL artemether‑lumefantrine (n 23), AS + SP sulfadoxine‑
pyrimethamine (n 24)
Table 3 Comparison of the frequency of dhfr gene haplotypes in four sentinel sites in 2011
* Fisher’s exact test
** Significantly higher than Kassala (Fisher’s exact p = 0.0001), Kosti (Fisher’s exact p = 0.0002) and Sennar (Fisher’s exact p = 0.0002)
Number of mutations Mutation haplotype KASSALA N = 79 GEDAREF N = 96 SENNAR N = 98 KOSTI N = 92 p value*
None dhfr wild type 2 (2.5 %) 2 (2.1 %) 4 (4.1 %) 7 (7.6 %) 0.27
Double N51I, S108 N 73 (92.4 %) 67 (69.8 %) 87 (88.8 %) 78 (84.9 %) <0.001
N51I, C59R 0 1 (1.0 %) 0 1 (1.0 %)
Triple N51I, C59R, S108 N 4 (5.1 %) 26** (27.1 %) 7 (7.1) 6 (6.5 %) <0.001
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27.1 %. There is also a significant displacement of the dhfr 
wild-type haplotype (from 10.6  % in 2003 [17] to 2.1  % 
in 2011, p = 0.018, Fisher’s exact test). In the dhps gene 
there is emergence of the point mutation S436A, which 
was absent in the two cited surveys performed in 2003 
[17, 19]. Other significant changes are related to combi-
nation of mutations in the dhps with the dhfr genes. The 
quintuple mutant N51I/C59R/S108  N +  A437G/K540E, 
which was reported in very low frequencies in 2003 iso-
lates from Gedaref (1/146, 0.7 %) [19], increased to 27.1 % 
(26/96) in the 2011 sample from Gedaref (p  <  0.001, 
Fisher’s exact test). Additionally, the proportion of iso-
lates with quintuple/sextuple mutations in Gedaref has 
increased from 13.1  % in 2003 [19] to 38.6  % in 2011 
(Fisher’s exact test, p < 0.001).
Discussion
The high cure rate of AL in the present study was consist-
ent with reports from other endemic areas [20, 21]. The 
proportion of patients who are parasitaemic on day 3 of 
treatment is the indicator used during routine monitor-
ing to identify suspected artemisinin resistance in P. falci-
parum [22]. With one exception, all patients treated with 
AL were negative for asexual parasitaemia on day 3, indi-
cating that artemether effectively reduced the parasite 
biomass [23]. Artemisinin resistance, defined as a delayed 
parasite clearance time, has so far been reported only in 
Southeast Asia [24, 25]. A clear distinction must be made 
between treatment failure, i.e., the absence of resolution 
of parasitaemia and clinical signs after anti-malarial 
treatment, and true resistance to an anti-malarial drug 
[26]. The outcome of a therapeutic efficacy test is influ-
enced by a triad of the patient’s immunity, the parasite’s 
susceptibility to the drug and pharmacokinetics, which 
may vary from person to person. Lumefantrine is highly 
lipophilic, and its bioavailability depends on concur-
rent food intake, which could be impaired during acute 
malaria [27]. The definitive confirmation of resistance to 
an anti-malarial drug requires proof that the parasites are 
recrudescent and demonstration that an effective blood 
concentration of the drug or its metabolites has been 
maintained for at least four parasitic cycles (approxi-
mately 6  days) [28]. Pharmacokinetic studies required 
to provide such evidence are not usually performed in 
standard therapeutic efficacy studies aimed at helping 
policy makers to make decisions regarding the selec-
tion of first-line and second-line treatments for uncom-
plicated malaria [5]. In the absence of pharmacokinetic 
data, the causes of the treatment failure in the present 
study may only be speculated upon and it could be due to 
true drug resistance or poor bioavailability of the drugs.
The PCR-corrected cure rates of AS +  SP in Gedaref 
in 2014–15 were 86.5  %, below the WHO threshold for 
changes in treatment policy [11]. In all other sites tested, 
however, AS + SP was efficacious, with cure rates rang-
ing from 95.6 to 100 %. In contrast to the present study 
conducted in Kassala in 2011, which found a cure rate 
of 98.6  %, a subsequent study in 2012 in the same site 
Table 4 Comparison of the frequency of dhps gene haplotypes in four sentinel sites in Sudan 2011
a Kosti wild type is significantly higher than Gedaref (Chi square = 31.93, p < 0.001), Kassala (Chi Square = 38.12, p < 0.001) and Sennar (Chi square = 21.97, p < 0.001)
b Kosti mutant is significantly lower than Gedaref (Chi square = 7.07, p = 0.008), not significantly different from Kassala (Chi Square = 0.54 p = 0.462) or Sennar (Chi 
square = 1.10, p = 0.295)
c The proportion of Kosti mutant isolates is significantly lower than Gedaref p < 0.001, Kassala, p < 0.001 and Sennar p < 0.001, Fisher’s exact test
d Fisher’s exact test
Number of muta‑
tions
Dhps haplotype Kassala Gedaref Sennar KostiI Pearson’s Chi 
square
p value
None wild dhps type 14 (17.3 %) 22 (22.9 %) 30 (30.0 %) 57(64.0 %)a 52.127 <0.001
Single S436A 0 2 1 2
A437G 0 4 0 4
K540E 0 3 1 0
A581G 1 0 1 1
S436C 0 0 9 0
Double A437G, K540E 26 (32.1 %) 44 (45.8 %) 34 (34.0 %) 24 (27.0 %)b 7.824 0.050
S436C, A581G 0 0 2 0
S436C, K540E 0 0 1 0
A437G, A581G 0 0 1 0
Triple S436A, A437G, K540E 6 (7.4 %) 6 (6.2 %) 0 0
A437G, K540E, A581G 33 (40.7 %) 15 (15.6 %) 20 (20 %) 1 (1 %)c <0.001d
Quadruple S436A, A437G, K540E, A581G 1 0 0 0
Total 81 96 100 89
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reported a PCR-corrected per-protocol cure rate of 
93.7 % with AS + SP [29]. This trend indicates a possible 
decline in treatment efficacy. Apart from the obvious dis-
advantages to the patient being treated with an ineffec-
tive drug, continued use of an ACT in which the partner 
drug is failing would compromise the efficacy of the arte-
misinin component and expose the parasites to selection 
pressure for artemisinin resistance. No asexual parasites 
were detected on day 3 by microscopy, indicating that 
the artesunate component had achieved its expected ini-
tial rapid reduction in the parasite biomass [23]. Patients 
who failed treatment likely had submicroscopic levels of 
parasitaemia on day 3. Therefore, SP failed to clear the 
residual parasites, leading to recrudescence. This was 
also supported by the fact that almost all of the treatment 
failures were late treatment failures (37/38). The AS + SP 
treatment failure in Gedaref in the 2014–15 season sur-
passed the failure rate of 10  % recommended by the 
WHO for policy change and, therefore, underscores the 
need to update the malaria treatment policy in Sudan.
In the present findings, the risk of treatment failure 
was clearly much higher in children who are less than 
5 years of age compared to adults. The much higher rate 
of treatment failure in young children could be associated 
with age-related immunity. Theander [30] reported that 
the outcome of malaria infection in this area is strongly 
associated with age-related immunity. Djimdé et al. [31] 
found that the ability to clear chloroquine-resistant para-
sites was strongly associated with age, which they regard 
as the most consistent correlate of protective immunity 
in areas endemic for P. falciparum malaria. In the pre-
sent study, the risk of treatment failure was clearly much 
higher in children less than 5  years of age compared to 
adults. It is also notable that the age composition in the 
samples from the different sites shows wide variations. 
This means that the age composition of the study sample 
Table 5 The types and frequencies of SP resistance haplotypes detected in both dhfr and dhps genes in isolates from four 
sentinel sites in Sudan in 2011
* Associations tested for the main groups, using the Chi square test, Fisher’s exact test was used when the number of observations was less than five
Haplotypes Kassala, 
n = 79
Gedaref, n = 96 Sennar, n = 98 Kosti, n = 88 Total p value*
N (%) N (%) N (%) N (%) N
dhfr wild type + dhps wild type 1 (1.3) 1 (1) 4 (4.1) 6 (6.8) 12 0.133
All double mutants 9 (11.4) 17 (17.7) 23 (23.5) 48 (54.5) 97 <0.001
dhfr N51I, S108 N + dhps wild type 9 (11.4) 17 (17.7) 23 (23.5) 47 (53.4) 96 <0.001
dhfr wild type + dhps A437G + K540E 0 (0) 0 (0) 0 (0) 1 (1.1) 1
All triple mutants 6 (7.6) 13 (13.5) 15 (15.3) 11 (12.5) 45 0.467
dhfr N51I, C59R, S108 N + dhps wild type 4 (5.1) 4 (4.2) 3 (3.1) 4 (4.5) 15 0.911
dhfr N51I, S108 N + dhps S436A 0 (0) 0 (0) 1 (1.0) 2 (2.3) 3
dhfr C59R, S108 N + dhps S436A 0 (0) 1 (1) 0 (0) 0 (0) 1
dhfr N51I, S108 N + dhps A437G 0 (0) 4 (4.2) 0 (0) 4 (4.5) 8
dhfr N51I, S108 N + dhps K540E 0 (0) 3 (3.1) 1 (1.0) 0 (0) 4
dhfr N51I, S108 N + dhps A581G 1 (1.3) 0 (0) 1 (1.0) 1 (1.1) 3
dhps A437G, K540E, A581G 1 (1.3) 1 (1) 0 (0) 0 (0) 2
dhfr N51I, S108 N + dhps S436C 0 (0) 0 (0) 9 (9.2) 0 (0) 9
All quadruple mutants 25 (31.6) 28 (29.2) 38 (38.8) 20 (22.7) 111 0.125
dhfr N51I, C59R, S108 N + dhps S436A 0 (0) 1 (1) 0 (0) 0 (0) 1
dhfr N51I, S108 N + dhps A437G, K540E 25 (31.6) 27 (28.1) 34 (34.7) 20 (22.7) 106 0.325
dhfr N51I, S108 N + dhps A437G, A581G 0 (0) 0 (0) 1 (1.0) 0 (0) 1
dhfr N51I, S108 N + dhps A436C, K540E 0 (0) 0 (0) 1 (1.0) 0 (0) 1
dhfr N51I, S108 N + dhps A436C, A581G 0 (0) 0 (0) 2 (2.0) 0 (0) 2
All quintuple mutants 37 (46.8) 33 (34.4) 14 (14.3) 3 (3.4) 87 <0.001
dhfr N51I, C59R, S108 N + dhps A437G, K540E 0 (0) 17 (17.7) 0 (0) 2 (2.3) 19 <0.001
dhfr N51I, S108 N + dhps S436A, A437G, K540E 5 (6.3) 5 (5.2) 0 (0) 0 (0) 10 0.004
dhfr N51I, S108 N + dhps A437G, K540E, A581G 32 (40.5) 11 (11.5) 14 (14.3) 1 (1.1) 58 <0.001
All sextuple mutants 1 (1.3) 4 (4.2) 4 (4.1) 0 (0) 9
dhfr N51I, C59R, S108 N + dhps S436A, A437G, K540E 0 (0) 1 (1) 0 (0) 0 (0) 1
dhfr N51I, C59R, S108 N + dhps A437G, K540E, A581G 0 (0) 3 (3.1) 4 (4.1) 0 (0) 7
dhfr N51I, S108 N + dhps S436A, A437G, K540E, A581G 1 (1.3) 0 (0) 0 (0) 0 (0) 1
Page 10 of 13Adeel et al. Malar J  (2016) 15:285 
in this area could influence the overall results of a trial, a 
fact that should be taken into consideration in the plan-
ning and analysis of trials in such a setting. Because the 
blood levels of the drugs have not been measured in the 
present study, the possible impact of pharmacokinetic 
factors that might contribute to the increased risk of SP 
treatment failure in young children cannot be ruled out 
[32].
Few studies have been performed to compare the 
impact of AL and AS +  SP on gametocytaemia [33]. In 
the present study, there was no significant difference in 
the clearance of microscopic gametocytaemia between 
AL and AS + SP. This is in line with a trial reported by 
van den Boek et al. [34], which compared the efficacy of 
three artemisinin-based combinations, AS + SP, AL and 
artesunate +amodiaquine (AS  +  AQ). They found no 
significant differences between these drugs on gameto-
cytaemia by day 28. However, another study in Yemen 
reported a significantly higher rate of gametocyte clear-
ance with AL compared to AS  +  SP [35]. The present 
study also showed no significant difference between the 
two drugs in their effect on gametocyte carriage as meas-
ured by PGW.
The two main factors in the spread of anti-malarial 
drug resistance are drug pressure and human migration 
[36]. Because of its long elimination half-life, SP is par-
ticularly vulnerable for the induction of resistance by 
drug pressure [37]. Drug pressure is an important fac-
tor in Sudan, where self-medication and sub dosing with 
anti-malarial drugs is common [38–40]. It is not surpris-
ing that the failure of AS + SP first emerged in Gedaref 
or Eastern Sudan in close proximity to the borders with 
Ethiopia. This area has historically been a hotbed for 
drug-resistant malaria. Chloroquine resistance was first 
reported in the eastern Sudan, particularly in the refugee 
camps [41, 42]. The highest rate of treatment failure of 
SP as a monotherapy has also been reported in Gedaref 
[4]. Mass population movements take place in this region 
and camps hosted refugees from Eritrea and Ethiopia for 
decades, in addition to the continuous exchange of popu-
lations with Ethiopia and Eritrea for economic reasons. 
SP was introduced as a first-line treatment for falcipa-
rum malaria in Ethiopia in 1998–1999, but within a few 
years, the mean SP treatment failure rates reached 35.9 
and 71.8 % for day 14 and day 28, respectively [43]. Popu-
lation movements are believed to play an important role 
in the epidemiology of anti-malarial drug resistance in 
Africa [44]. The temporal and regional changes in drug 
resistance observed in the present study highlight the 
need for further studies to understand the exact contri-
bution of population movements and other demographic 
factors in the emergence and spread of drug resistance in 
this area.
A number of mutations in the dhfr and dhps genes have 
been associated with SP resistance [6, 45–48]. In Africa, 
SP resistance is strongly associated with combinations 
of five single point mutations, dhfr N51I, C59R, S108 N, 
and dhps A437G and K540E [49–52]. The prevalence of 
the different antifolate markers in the four sites studied 
in the present study indicates varying degrees of selec-
tion for resistant haplotypes in the different sites. The 
emergence and increased frequency of the C59R muta-
tion in the four sites tested in the present study is par-
ticularly interesting. In contrast to the situation in other 
parts of Africa, the dhfr triple mutation N51I, C59R, 
S108 N has maintained a low frequency in eastern Sudan 
because of the low prevalence of the C59R mutation. 
The C59R mutant was reported to be absent in eastern 
Sudan isolates in 2003 [17, 53], and it was found at a 
very low frequency of 0.6 % in another study [19]. After 
analysis of isolates collected in 2007, Menegon et al. also 
reported the absence of the C59R mutation in samples 
from Gedaref, but it was present in isolates from Gezira 
in central Sudan [54]. Gadalla et  al. [29] reported a low 
prevalence (1/59) of this mutant in isolates collected in 
Kassala in 2012. Longitudinal studies in eastern Sudan 
and in Gedaref have indicated that the prevalence of the 
S108 N mutation has gradually increased since 1990 [55]. 
In 2012, isolates from Kassala, the prevalence of the dhfr 
double mutant N51I + S108 N reached 100 %, with a rare 
triple mutant N51I + C59R + S108 N haplotype in one 
individual [29]. In the present study, the increase in the 
prevalence of the triple mutation dhfr I51/R59/N108 is 
associated with displacement of the dhfr double mutant 
in Gedaref, indicating that the triple mutant has emerged 
in the background of a double mutant dhfr, which has 
previously maintained a high prevalence level in this area 
as well as in locations in Sudan.
Mutations in the dhps gene, which confer resistance 
to the sulfadoxine component of SP, appeared in Africa 
in 1990s [52]. In eastern Sudan, the dhps double mutant 
A437G + K540E was absent in Gedaref (Asar village) in 
1993; it appeared in 1998 and increased dramatically in 
2000 following the use of SP as a first-line treatment for 
malaria [55]. An interesting finding in the present study 
was that for the first time in Sennar, mutant S436C was 
detected in 12 isolates. Malisa et  al. also reported this 
mutant at a low frequency for the first time in Tanzania, 
also in the context of SP resistance and drug selection 
pressure [56]. They attributed their ability to detect this 
rare mutant to a larger sample size used and the inability 
of alternative methodologies to detect a rare codon 436 
mutation. However, the frequency of this mutant in our 
Sennar sample was not rare (12 %). Moreover, the mutant 
was not detectable in the other three sites assessed 
together in our study. This could possibly be another 
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manifestation of selection pressure. The present study 
detected other changes in the dhps suggestive of selec-
tion for resistant haplotypes, including the emergence of 
the triple mutant S436A + A437G + K540E. Apart from 
Gedaref, the cure rates were still high in the other three 
sentinel sites, but the high prevalence of quintuple muta-
tions in Kassala and Gedaref and the temporal changes 
in the frequency of these markers in Gedaref should be 
cause for concern about the emergence and spread of SP 
resistance on a wider scale within the country.
The present study shows significant regional differen-
tiation in the SP molecular markers in the four locations 
covered by the molecular markers survey. In contrast to 
the high prevalence of quintuple mutants found in Kas-
sala and Gedaref, which are close to the Ethiopia and 
Eritrea borders, the majority of samples from Kosti are 
triple mutants or less. This differentiation is probably due 
to interplay of different demographic and genetic factors 
as well as the effect of drug pressure and the influence 
of human migration on the dispersal of resistant para-
sites. In Ethiopia, the prevalence of molecular mutations 
associated with SP resistance is high, reaching satura-
tion levels [57, 58]. Pearce et al. [44] used the microsat-
ellite polymorphism flanking the dhps gene to determine 
which resistance alleles shared common ancestry and 
found that dhps alleles from Ethiopia and eastern Sudan 
have a distinct lineage that is unique to the region. This 
lineage is believed to have emerged in Ethiopia and 
Sudan at the same time.
Molecular markers could constitute a powerful tool 
for the surveillance of SP resistance. By following the 
changes in SP resistance markers, it could be possible 
to follow the dispersal of resistant parasites and identify 
regions of significant parasite exchange in real time. This 
is particularly important in areas where molecular mark-
ers have been suggested as tools to track the importation 
of resistant parasites into malaria elimination areas [59]. 
There is a need high for resolution mapping of parasite 
genetics to be able to detect changes in drug resistance 
genes. In this regard, the importance of studying the 
regional variations in the frequencies of molecular mark-
ers within these countries should be highlighted. Some 
published reports have taken regional data as a national 
baseline to assess changes in other regions of the country. 
The regional differences shown in the present study, even 
among locations within Eastern Sudan, demonstrate that 
such an approach could lead to erroneous conclusions. 
The distance between Gedaref and Kassala is 200  km. 
However, the frequency of the dhfr 59R mutant is 5.1 % in 
Kassala and 28.1 % in Gedaref. The frequency of A436C 
is 12  % in Sennar and 0  % in all of the other sites. The 
present study also underscores the importance of col-
laboration between neighbouring endemic countries in 
the surveillance of drug resistance and the formulation of 
drug policies.
Conclusions
Of particular concern is the finding in Gedaref, where the 
therapeutic efficacy of AS + SP is below the level recom-
mended for treatment policy change, combined with a 
high prevalence of quintuple or sextuple dhfr/dhps muta-
tions. Similary in Kassala, a high prevalence of quintuple 
or sextuple haplotypes was observed. This underscores 
the need to begin to review the national treatment pol-
icy. The finding of a high efficacy of artemether-lume-
fantrine in the study areas supports its use as a safe and 
effective second-line treatment against uncomplicated 
falciparum malaria in Sudan, in line with the current 
treatment policy. The survey of molecular markers for SP 
resistance showed regional differentiation and the selec-
tion of SP resistance haplotypes. This regional differen-
tiation should be taken into account in the analysis of 
countrywide data. This study highlights the significance 
of considering human migration in the spread of drug 
resistance and the value of molecular marker studies in 
tracking the dispersal of resistant parasites.
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